Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate CancerDana E. Rathkopf, Howard I. Scher, Martin Fleisher et al.|Journal of Clinical Oncology|2013Cited by 264